225 related articles for article (PubMed ID: 31101554)
1. Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Novelli A; Di Vico IA; Terenzi F; Sorbi S; Ramat S
Parkinsonism Relat Disord; 2019 Jul; 64():352-353. PubMed ID: 31101554
[No Abstract] [Full Text] [Related]
2. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Delea TE; Thomas SK; Hagiwara M; Mancione L
Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
5. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
6. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
8. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S
J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090
[TBL] [Abstract][Full Text] [Related]
9. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
10. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
[TBL] [Abstract][Full Text] [Related]
11. Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience.
Szász JA; Dulamea AO; Constantin VA; Mureşanu DF; Dumbravă LP; Tiu C; Jianu DC; Simu M; Ene A; Axelerad A; Falup-Pecurariu C; Lungu M; Danci AG; Sabau M; Strilciuc Ş; Popescu BO
Am J Ther; 2024 May-Jun 01; 31(3):e209-e218. PubMed ID: 38460175
[TBL] [Abstract][Full Text] [Related]
12. Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA
Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
[TBL] [Abstract][Full Text] [Related]
13. Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Sampaio C; Ferreira JJ
Nat Rev Neurol; 2010 Nov; 6(11):590-1. PubMed ID: 21048799
[No Abstract] [Full Text] [Related]
14. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
17. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
Destée A; Rérat K; Bourdeix I
Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
[TBL] [Abstract][Full Text] [Related]
18. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Catalán MJ; Escribano PM; Alonso-Frech F
Mov Disord; 2017 Apr; 32(4):624-625. PubMed ID: 28116835
[No Abstract] [Full Text] [Related]
19. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
Brooks DJ; Leinonen M; Kuoppamäki M; Nissinen H
J Neural Transm (Vienna); 2008 Jun; 115(6):843-9. PubMed ID: 18259682
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
